CJC 1295 (No DAC)
CJC-1295 (No DAC) is a synthetic analog of growth hormone–releasing hormone (GHRH) studied for its ability to stimulate natural growth hormone pulses. Unlike the DAC-modified version, the No DAC variant is short-acting and designed to amplify physiologic GH secretion patterns. In research settings, it is explored for its influence on GH–IGF-1 signaling, recovery pathways, and endocrine rhythm regulation. Intended strictly for laboratory and research use.
Price range: 58,00 € through 103,00 €
Quality Certificates
Independent third-party lab analysis (CoA) - from our own in-house brand.
CJC-1295 (No DAC) - Short-Acting Growth Hormone Releasing
Description
CJC-1295 (No DAC) is a modified GHRH analog engineered to stimulate endogenous growth hormone release from the anterior pituitary. It binds to GHRH receptors on somatotroph cells, enhancing natural pulsatile GH secretion. The No DAC version lacks the drug affinity complex that prolongs half-life in the DAC formulation, resulting in shorter systemic activity.
This shorter-acting profile allows researchers to study physiologic pulse amplification rather than sustained hormone elevation. CJC-1295 (No DAC) is often investigated in experimental models examining growth hormone rhythm optimization, IGF-1 pathway engagement, and endocrine recovery signaling.
Clinical Status
Human RCT ▣ | Observational ▣ | Animal ✔ | In vitro ✔
Primarily studied in preclinical and exploratory human growth hormone modulation research contexts.
Mechanism of Action
CJC-1295 (No DAC) stimulates growth hormone release by binding to GHRH receptors in the pituitary gland. This activation enhances natural GH pulses without directly supplying exogenous hormone.
Benefits
- Enhances natural pulsatile growth hormone secretion:
CJC-1295 (No DAC) amplifies endogenous growth hormone release by directly stimulating the GHRH receptor pathway in the anterior pituitary. Growth hormone is physiologically secreted in discrete pulses, with peak amplitude occurring during deep sleep phases. Rather than producing continuous elevation, CJC-1295 increases the magnitude of these pulses while preserving their rhythmic nature. This pulsatile enhancement is central to maintaining receptor sensitivity and preventing desensitization associated with sustained hormone exposure. The short-acting profile allows GH levels to rise and fall within natural regulatory parameters. - Selective engagement of the GHRH receptor cascade:
CJC-1295 (No DAC) binds specifically to the growth hormone–releasing hormone receptor (GHRH-R), a G-protein–coupled receptor expressed on somatotroph cells. Activation of this receptor increases adenylate cyclase activity, elevating intracellular cAMP levels. This rise in cAMP activates protein kinase A, leading to enhanced transcription and exocytosis of growth hormone. Unlike ghrelin-based peptides that act through the GHS-R1a receptor, CJC-1295 does not directly stimulate appetite-related hypothalamic pathways. This receptor specificity differentiates it mechanistically from GHRP compounds. - Preserves hypothalamic somatostatin regulation:
The hypothalamus tightly controls GH release through a balance between GHRH stimulation and somatostatin inhibition. Because CJC-1295 stimulates endogenous pathways rather than bypassing them, somatostatin feedback remains active. This allows the body to modulate hormone output dynamically based on physiologic demand. Maintaining this inhibitory counterbalance is important in experimental models examining long-term endocrine stability. - Supports downstream IGF-1–mediated anabolic signaling:
Once growth hormone is released, it stimulates hepatic production of insulin-like growth factor 1 (IGF-1). IGF-1 activates intracellular pathways including PI3K/Akt and mTOR, which regulate protein synthesis and cellular growth. Through this two-step endocrine cascade, CJC-1295 indirectly influences tissue adaptation and recovery-related signaling. This layered activation preserves physiological hierarchy rather than directly activating peripheral receptors. - Short-acting profile enables pulse timing studies:
Unlike the DAC-modified formulation, the No DAC version lacks albumin-binding extension and therefore has a shorter half-life. This transient activity allows researchers to evaluate timing-dependent endocrine responses and synchronization with circadian cycles. Pulse timing plays a critical role in how tissues respond to growth hormone exposure. By aligning with physiologic rhythms, CJC-1295 (No DAC) supports research focused on hormone pattern optimization rather than continuous stimulation. - Influences sleep-associated growth hormone peaks:
Growth hormone secretion is closely linked to slow-wave sleep. Amplifying physiologic GH pulses may enhance the magnitude of nocturnal hormone peaks in experimental models. This connection places CJC-1295 within integrated sleep–endocrine research frameworks. Rather than inducing sleep directly, it operates within hormonal cycles that coincide with restorative phases. - Distinct from ghrelin mimetics and appetite-driven peptides:
GHRP compounds stimulate growth hormone release via ghrelin receptor activation and may influence hunger pathways. CJC-1295 operates exclusively through the GHRH receptor pathway, avoiding direct activation of neuropeptide Y–mediated appetite signaling. This distinction makes it more focused on pituitary modulation than hypothalamic hunger circuits. The absence of strong appetite stimulation differentiates its systemic profile. - Facilitates structured endocrine modulation research:
Because it enhances natural hormone pulses rather than replacing GH, CJC-1295 supports investigation into physiologic endocrine adaptation. The preservation of feedback loops, receptor sensitivity, and pulse rhythm allows researchers to examine nuanced hormonal modulation. This precision positions the No DAC variant within rhythm-aligned growth hormone research rather than sustained supraphysiologic exposure models. - Integrates within broader neuroendocrine coordination networks:
Growth hormone interacts with metabolic regulation, connective tissue remodeling, and circadian timing systems. By amplifying endogenous GH pulses, CJC-1295 participates in this integrated neuroendocrine network. Its activity reflects coordinated communication between hypothalamus, pituitary, and peripheral tissues. This systems-level positioning differentiates it from peptides that act directly at peripheral receptors without upstream regulatory integration.
Research Data
| Study / Model | Reported effect |
|---|---|
| Healthy adult human pharmacokinetic study | ↑ GH pulse amplitude within 15 minutes; return to baseline within ~30 minutes |
| Rat pituitary somatotroph cultures | ↑ GHRH receptor activation and dose-dependent GH release |
| Subcutaneous injection in human subjects | ↑ IGF-1 levels sustained over 24 hours following single dose |
| Combined CJC-1295 + Ipamorelin protocol (preclinical) | Synergistic ↑ in GH secretion preserving natural pulsatility |
| Aged rodent model | ↑ lean body mass markers and ↓ adipose tissue accumulation |
| In vitro GHRH-R binding assay | Enhanced receptor affinity compared to native GHRH (1-29) |
Stack Suggestions
CJC-1295 (No DAC) is often combined in research with:
- CJC-1295 (No DAC) + Ipamorelin → Synergistic GH release through complementary GHRH and ghrelin receptor pathways.
- CJC-1295 (No DAC) + Tesamorelin → Amplified GHRH stimulation for enhanced lipolytic and metabolic research models.
- CJC-1295 (No DAC) + BPC-157 → Supports tissue repair while elevating GH-mediated regenerative signaling.
- CJC-1295 (No DAC) + MOTS-c → Combines mitochondrial efficiency with GH-driven metabolic activity.
⚠ Stacks are for experimental design only; not safety or efficacy guidance.
Pen Dosage Chart
| CJC 1295 (No DAC) Pen 5 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 10 clicks = 0.25 mg |
| CJC 1295 (No DAC) Pen 10 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Dosage & Protocols Variations
Standard Research Protocol
- Dose: 0.1 – 0.2 mg (variant 5 mg pen = 4–8 clicks / variant 10 mg pen = 2–4 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1 – 2× daily (pre-sleep and/or post-workout)
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline GH pulse amplification in research models.
Therapeutic Research Protocol
- Dose: 0.2 – 0.3 mg (variant 5 mg pen = 8–12 clicks / variant 10 mg pen = 4–6 clicks)
- Duration: 12 weeks
- Frequency: 2 – 3× daily, spaced 6 – 8 hours apart
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Higher-frequency models exploring recovery and lean mass outcomes.
Stacked Protocol (CJC-1295 No DAC + Ipamorelin)
- Dose: 0.1 mg CJC-1295 + 0.1 – 0.2 mg Ipamorelin (variant 5 mg pen = 4 clicks / variant 10 mg pen = 2 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1 – 3× daily, on empty stomach
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Synergistic GHRH + GHRP combination for amplified pulsatile GH release.
Possible Side Effects
CJC-1295 (No DAC) is generally well-tolerated in animal studies and limited human research.
Reported side effects are typically mild and transient:
- Localized redness, itching, or irritation at the injection site.
- Transient facial flushing or warmth shortly after administration.
- Mild headache or lightheadedness during initial dosing.
- Temporary water retention or peripheral swelling.
- Occasional sensations of tingling or numbness in the extremities.
No evidence of significant endocrine disruption, hepatic, or cardiovascular adverse effects has been observed in available data when used within researched dose ranges.
Product Attributes
- CAS #: 863288-34-0
- Molecular Formula: C152H252N44O42
- Sequence (AA): YADAIFTQSYRKVLAQLSARKLLQDIMSR
- Molecular Weight: ~3367.9 g/mol
- PubChem CID: 56841945
- Half-Life: ~30 minutes
- Synonyms: Mod GRF (1-29), Modified GRF 1-29, CJC-1295 without DAC, Sermorelin analog
- Type: Synthetic research peptide (GHRH analog)
- Research Focus: Growth Hormone & Anti-Aging, Recovery & Performance
Scientific References
- A new long-acting analog of growth hormone-releasing hormone with prolonged half-life in patients with adult GH deficiency Human RCT | Observational
- Sustained-release GHRH analog increases GH and IGF-I in healthy adults Human RCT
- Effects of GHRH analog CJC-1295 on growth hormone and IGF-I levels Human RCT | Observational
- GHRH analogs and their potential role in stimulating endogenous GH secretion Animal | In vitro
- Structure-activity studies of GHRH analogs with extended biological half-life In vitro
- Growth hormone-releasing hormone and its analogs: clinical applications and mechanisms Observational | Animal | In vitro
- CJC-1295 research summary: mechanism, dosage, and effects Observational | Animal
- Pulsatile GH secretion induced by GHRH analog administration in healthy subjects Human RCT
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
